Nektar Therapeutics | Small-cap | Healthcare
$49.89
1.80%
| Nektar Therapeutics Stock Comparison:
Nektar Therapeutics vs VertexNektar Therapeutics vs AlnylamNektar Therapeutics vs RecursionNektar Therapeutics vs AdaptiveNektar Therapeutics vs Harmony BiosciencesNektar Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 11.2M
Gross Profit 11.2M 100.00%
Operating Income -35.8M -320.21%
Net Income -41.6M -372.20%
EPS (Diluted) $-2.95

Balance Sheet Metrics

Total Assets 256.2M
Total Liabilities 242.5M
Shareholders Equity 13.7M
Debt to Equity 17.65

Cash Flow Metrics

Operating Cash Flow -54.7M
Free Cash Flow -49.1M

Revenue & Profitability Trend

Nektar Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i98.4M90.1M92.1M101.9M152.9M
Cost of Goods Sold i30.7M33.8M21.6M24.9M19.5M
Gross Profit i67.7M56.4M70.4M77.0M133.4M
Gross Margin % i68.8%62.5%76.5%75.6%87.3%
Operating Expenses
Research & Development i120.9M114.2M218.3M400.3M408.7M
Selling, General & Administrative i76.8M77.4M92.3M122.8M104.7M
Other Operating Expenses i-----
Total Operating Expenses i197.7M191.6M310.7M523.1M513.4M
Operating Income i-129.9M-135.2M-240.2M-446.1M-379.9M
Operating Margin % i-132.0%-150.0%-261.0%-437.8%-248.5%
Non-Operating Items
Interest Income i14.5M19.0M6.8M2.7M18.3M
Interest Expense i28.1M25.3M28.9M47.3M37.1M
Other Non-Operating Income24.3M-134.7M-102.6M-32.6M-45.2M
Pre-tax Income i-119.2M-276.3M-365.0M-523.3M-443.9M
Income Tax i-239.0K-200.0K3.2M557.0K493.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-119.0M-276.1M-368.2M-523.8M-444.4M
Net Margin % i-120.9%-306.3%-400.0%-514.0%-290.6%
Key Metrics
EBITDA i-111.4M-114.6M-220.5M-453.8M-347.5M
EPS (Basic) i$-8.70$-1.45$-1.97$-2.86$-2.49
EPS (Diluted) i$-8.70$-1.45$-1.97$-2.86$-2.49
Basic Shares Outstanding i13710733190001000187138000183298000178581000
Diluted Shares Outstanding i13710733190001000187138000183298000178581000

Income Statement Trend

Nektar Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i44.3M35.3M88.2M25.2M199.0M
Short-term Investments i211.0M268.3M416.8M708.7M862.9M
Accounts Receivable i01.2M6.0M22.5M38.9M
Inventory i016.1M19.2M15.8M15.3M
Other Current Assets--15.8M23.3M21.9M
Total Current Assets i261.3M330.7M546.0M795.6M1.1B
Non-Current Assets
Property, Plant & Equipment i12.8M100.0M177.6M279.5M281.4M
Goodwill i-0153.0M153.0M153.0M
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets4.6M4.6M2.2M2.7M1.5M
Total Non-Current Assets i42.6M67.3M164.6M321.6M400.8M
Total Assets i303.8M398.0M710.6M1.1B1.5B
Liabilities
Current Liabilities
Accounts Payable i11.6M9.8M13.0M9.7M22.1M
Short-term Debt i19.9M19.3M18.7M17.4M13.9M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i61.4M51.3M68.2M85.2M115.8M
Non-Current Liabilities
Long-term Debt i82.7M98.5M112.8M125.7M136.4M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities99.0M117.3M162.9M199.0M209.3M
Total Non-Current Liabilities i181.7M215.8M275.8M352.5M345.7M
Total Liabilities i243.1M267.0M344.0M437.7M461.5M
Equity
Common Stock i19.0K19.0K19.0K19.0K18.0K
Retained Earnings i-3.6B-3.5B-3.2B-2.8B-2.3B
Treasury Stock i3.0M----
Other Equity-----
Total Shareholders Equity i60.7M131.0M366.6M679.5M1.1B
Key Metrics
Total Debt i102.6M117.8M131.5M143.2M150.3M
Working Capital i199.9M279.4M477.8M710.4M1.0B

Balance Sheet Composition

Nektar Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-119.0M-276.1M-368.2M-523.8M-444.4M
Depreciation & Amortization i4.4M7.8M13.0M14.1M14.2M
Stock-Based Compensation i21.6M33.4M57.3M94.7M94.3M
Working Capital Changes i-17.0M-2.7M20.4M-48.0K10.8M
Operating Cash Flow i-146.1M-281.3M-310.6M-404.5M-339.5M
Investing Activities
Capital Expenditures i-1.5M380.0K7.5M-15.0M-7.3M
Acquisitions i65.4M----
Investment Purchases i-261.7M-511.7M-467.9M-960.7M-987.5M
Investment Sales i340.4M650.9M826.2M1.2B1.5B
Investing Cash Flow i142.6M139.6M365.8M202.8M496.2M
Financing Activities
Share Repurchases i-3.0M----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i--00-250.0M
Financing Cash Flow i12.0M-750.0K3.0M42.5M
Free Cash Flow i-177.2M-193.5M-309.7M-427.6M-320.5M
Net Change in Cash i8.5M-141.7M56.0M-198.7M199.2M

Cash Flow Trend

Nektar Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -5.54
Forward P/E -61.82
Price to Book -28.03
Price to Sales 12.08
PEG Ratio -0.01

Profitability Ratios

Profit Margin -163.17%
Operating Margin -320.21%
Return on Equity -440.80%
Return on Assets -31.57%

Financial Health

Current Ratio 2.61
Debt to Equity -7.30
Beta 1.07

Per Share Data

EPS (TTM) $-8.64
Book Value per Share $-1.94
Revenue per Share $5.34

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
nktr916.3M-5.54-28.03-440.80%-163.17%-7.30
Vertex 101.2B28.085.8922.77%31.86%8.89
Alnylam 60.4B-211.56241.63-257.83%-12.96%1,093.31
Recursion 2.1B-2.862.27-86.34%22.65%9.58
Adaptive 1.9B-11.6810.68-57.60%-59.07%121.39
Harmony Biosciences 1.9B10.332.3827.58%23.42%22.43

Financial data is updated regularly. All figures are in the company's reporting currency.